Risuteganib: Broad-spectrum integrin inhibitor Treatment of diabetic macular edema Treatment of dry age-related macular degeneration

L. Ferro Desideri, A. Vagge, V. Testa, M. Nicolò, C. E. Traverso

Research output: Contribution to journalArticlepeer-review

Abstract

Although several anti-vascular endothelial growth factor (VEGF) agents have been largely employed for the treatment of various retinal diseases, other molecules with different therapeutic targets are being investigated. Among them, antiintegrin drugs have shown promising results for the treatment of ocular diseases. Risuteganib (ALG-1001, Luminate) is a novel anti-integrin drug formed by a synthetic arginyl-glycyl-aspartic (RGD) acid peptide which modulates the biological activities of several integrin isoforms. Results from phase II studies have outlined a promising clinical efficacy and tolerability profile for risuteganib in the treatment of diabetic macular edema and vitreous tractional macular syndrome. Moreover, ongoing trials are investigating its role for treating macular degeneration and retinal dystrophies. Further randomized, larger-scale trials will better characterize its potential clinical effectiveness for treating these vitreoretinal disorders.

Original languageEnglish
Pages (from-to)633-639
Number of pages7
JournalDrugs of the Future
Volume45
Issue number9
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Age-related macular degeneration
  • ALG-1001
  • Diabetic macular edema
  • Integrin inhibitors
  • Luminate
  • Risuteganib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Risuteganib: Broad-spectrum integrin inhibitor Treatment of diabetic macular edema Treatment of dry age-related macular degeneration'. Together they form a unique fingerprint.

Cite this